| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-13 11:51:58 UTC |
|---|
| Update Date | 2022-03-07 02:57:14 UTC |
|---|
| HMDB ID | HMDB0041991 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Pitavastatin |
|---|
| Description | Most statins are metabolised in part by one or more hepatic cytochrome P450 enzymes, leading to an increased potential for drug interactions and problems with certain foods (such as grapefruit juice). Pitavastatin appears to be a substrate of CYP2C9, and not CYP3A4 (which is a common source of interactions in other statins). As a result, pitavastatin is less likely to interact with drugs that are metabolized via CYP3A4, which might be important for elderly patients who need to take multiple medicines. Pitavastatin (usually as a calcium salt) is a member of the medication class of statins, marketed in the United States under the trade name Livalo. Like other statins, it is an inhibitor of HMG-CoA reductase, the enzyme that catalyses the first step of cholesterol synthesis. It has been available in Japan since 2003, and is being marketed under licence in South Korea and in India. It is likely that pitavastatin will be approved for use in hypercholesterolaemia (elevated levels of cholesterol in the blood) and for the prevention of cardiovascular disease outside South and Southeast Asia as well. |
|---|
| Structure | O[C@H](C[C@H](O)\C=C\C1=C(C2=CC=C(F)C=C2)C2=CC=CC=C2N=C1C1CC1)CC(O)=O InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| NK 104 | ChEBI | | NK-104 | ChEBI | | Pitavastatia | ChEBI | | Pitavastatine | ChEBI | | Pitavastatinum | ChEBI | | Pitavastatin calcium | HMDB | | Itavastatin | HMDB | | Nisvastatin | HMDB | | Pitavastatin lactone | HMDB | | (e,3R,5S)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid | MeSH | | Itavastatin calcium | MeSH |
|
|---|
| Chemical Formula | C25H24FNO4 |
|---|
| Average Molecular Weight | 421.4608 |
|---|
| Monoisotopic Molecular Weight | 421.168936466 |
|---|
| IUPAC Name | (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid |
|---|
| Traditional Name | pitavastatin |
|---|
| CAS Registry Number | 147511-69-1 |
|---|
| SMILES | O[C@H](C[C@H](O)\C=C\C1=C(C2=CC=C(F)C=C2)C2=CC=CC=C2N=C1C1CC1)CC(O)=O |
|---|
| InChI Identifier | InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m1/s1 |
|---|
| InChI Key | VGYFMXBACGZSIL-MCBHFWOFSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenylquinolines. These are heterocyclic compounds containing a quinoline moiety substituted with a phenyl group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Quinolines and derivatives |
|---|
| Sub Class | Phenylquinolines |
|---|
| Direct Parent | Phenylquinolines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Phenylquinoline
- 4-phenylpyridine
- Medium-chain hydroxy acid
- Medium-chain fatty acid
- Beta-hydroxy acid
- Fluorobenzene
- Halobenzene
- Halogenated fatty acid
- Heterocyclic fatty acid
- Hydroxy fatty acid
- Aryl fluoride
- Aryl halide
- Monocyclic benzene moiety
- Hydroxy acid
- Fatty acyl
- Fatty acid
- Pyridine
- Unsaturated fatty acid
- Benzenoid
- Heteroaromatic compound
- Secondary alcohol
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Azacycle
- Carboxylic acid derivative
- Organohalogen compound
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Organofluoride
- Organonitrogen compound
- Organooxygen compound
- Alcohol
- Organic nitrogen compound
- Carbonyl group
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 7.06 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.8152 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.85 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 127.6 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2490.3 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 222.9 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 195.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 184.7 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 309.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 477.0 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 413.5 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 144.0 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1003.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 458.2 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1312.5 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 298.0 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 341.1 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 335.4 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 169.7 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 71.4 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Pitavastatin,1TMS,isomer #1 | C[Si](C)(C)O[C@@H](CC(=O)O)C[C@H](O)/C=C/C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 | 3606.4 | Semi standard non polar | 33892256 | | Pitavastatin,1TMS,isomer #2 | C[Si](C)(C)O[C@H](/C=C/C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C[C@@H](O)CC(=O)O | 3671.9 | Semi standard non polar | 33892256 | | Pitavastatin,1TMS,isomer #3 | C[Si](C)(C)OC(=O)C[C@H](O)C[C@H](O)/C=C/C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 | 3600.9 | Semi standard non polar | 33892256 | | Pitavastatin,2TMS,isomer #1 | C[Si](C)(C)OC(=O)C[C@@H](C[C@H](O)/C=C/C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)O[Si](C)(C)C | 3530.0 | Semi standard non polar | 33892256 | | Pitavastatin,2TMS,isomer #2 | C[Si](C)(C)O[C@H](/C=C/C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C[C@H](CC(=O)O)O[Si](C)(C)C | 3574.1 | Semi standard non polar | 33892256 | | Pitavastatin,2TMS,isomer #3 | C[Si](C)(C)OC(=O)C[C@H](O)C[C@@H](/C=C/C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)O[Si](C)(C)C | 3583.4 | Semi standard non polar | 33892256 | | Pitavastatin,3TMS,isomer #1 | C[Si](C)(C)OC(=O)C[C@@H](C[C@@H](/C=C/C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)O[Si](C)(C)C)O[Si](C)(C)C | 3534.7 | Semi standard non polar | 33892256 | | Pitavastatin,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@@H](CC(=O)O)C[C@H](O)/C=C/C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 | 3859.1 | Semi standard non polar | 33892256 | | Pitavastatin,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@H](/C=C/C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C[C@@H](O)CC(=O)O | 3904.3 | Semi standard non polar | 33892256 | | Pitavastatin,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)C[C@H](O)C[C@H](O)/C=C/C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 | 3852.1 | Semi standard non polar | 33892256 | | Pitavastatin,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C[C@@H](C[C@H](O)/C=C/C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)O[Si](C)(C)C(C)(C)C | 3981.9 | Semi standard non polar | 33892256 | | Pitavastatin,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@H](/C=C/C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C[C@H](CC(=O)O)O[Si](C)(C)C(C)(C)C | 4036.0 | Semi standard non polar | 33892256 | | Pitavastatin,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)C[C@H](O)C[C@@H](/C=C/C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)O[Si](C)(C)C(C)(C)C | 4026.9 | Semi standard non polar | 33892256 | | Pitavastatin,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C[C@@H](C[C@@H](/C=C/C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4148.8 | Semi standard non polar | 33892256 |
|
|---|